Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease

This publication has 69 references indexed in Scilit:

• A highly secreted sulphamidase engineered to cross the blood‐brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA
  EMBO Molecular Medicine, 2013
• Neonatal Gene Therapy With a Gamma Retroviral Vector in Mucopolysaccharidosis VI Cats
  Molecular Therapy, 2012
• Synergistic effects of central nervous system‐directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis
  Annals of Neurology, 2012
• Combined Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation in Mucopolysacharidosis Type VI
  2011
• Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
  Journal of Inherited Metabolic Disease, 2011
• Efficacy of a Combined Intracerebral and Systemic Gene Delivery Approach for the Treatment of a Severe Lysosomal Storage Disorder
  Molecular Therapy, 2011
• Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins
  Molecular Therapy, 2011
• Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene Transfer
  Molecular Therapy, 2011
• Immunomodulatory Gene Therapy Prevents Antibody Formation and Lethal Hypersensitivity Reactions in Murine Pompe Disease
  Molecular Therapy, 2010
• The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts
  Molecular Therapy, 2009